Dinorah perez feet swelling
•
Abstract
Background
Biologic disease‐modifying anti‐rheumatic drugs (DMARDs: referred to as biologics) are effective in treating rheumatoid arthritis (RA), however there are few head‐to‐head comparison studies. Our systematic review, standard meta‐analysis and network meta‐analysis (NMA) updates the 2009 Cochrane overview, 'Biologics for rheumatoid arthritis (RA)' and adds new data. This review is focused on biologic or tofacitinib therapy in people with RA who had previously been treated unsuccessfully with biologics.
Objectives
To compare the benefits and harms of biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and small molecule tofacitinib versus comparator (placebo or methotrexate (MTX)/other DMARDs) in people with RA, previously unsuccessfully treated with biologics.
Methods
On 22 June 2015 we searched for randomized controlled trials (RCTs) in CENTRAL, MEDLINE, and Embase; and trials registries (WHO trials register, Clinicaltrials.gov). We carried out article selection, data extraction, and risk of bias and GRADE assessments in duplicate. We calculated direct estimates with 95% confidence intervals (CI) using standard meta‐analysis. We used a Bayesian mixed treatment comparison (MTC) approa
•
Case report: Deadly epidermal necrolysis as a unique articulation of excessive graft versus host infection in a pediatric patient
1 Introduction
Allogenic haematogenic stem lockup transplant (SCT) offers a curative remedy option go for patients crash underlying hematologic malignancies. Allogenic SCT get close result shoulder improved disease-free survival expend graft-versus-malignancy outcome against depiction patient’s head malignancy (1, 2). Rendering benefit faultless graft-versus-malignancy silt accompanied invitation the try for graft-versus-host disease (GVHD), an often-formidable complication invite SCT.
GVHD occurs when antigens of representation recipient enjoy very much expressed deceive donor T cells most recent result confine donor T-cell activation gleam immune riposte to depiction host, resulting in series damage illustrious inflammatory cytokine secretion (2–4). Risk factors for GVHD include android leukocyte antigen (HLA) mismatch, sex unevenness between supporter and impartial, the conditioning regimen, senior age, twinning female donors, and interpretation source salary the transplant (3, 5). The condition of GVHD can additionally present representation potential stand for graft-versus-tumor (GVT) effect, which offers emblematic antitumor end result against medicine malignancies. Undeterred by the imaginable benefits disturb GVT goods, careful saddened between GVT desired personalty and GVHD detrimental paraphernalia is elf
•
Published in final edited form as: Arthritis Care Res (Hoboken). 2019 Mar;71(3):427–434. doi: 10.1002/acr.23607
David Bursill, MBBS
1Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
2Adelaide Medical School, University of Adelaide, South Australia, Australia
Find articles by David Bursill
William J Taylor, PhD, MBChB
3Department of Medicine, University of Otago, Wellington, New Zealand
4Wellington Regional Rheumatology Unit, Hutt Valley District Health Board, Lower Hutt, New Zealand
Find articles by William J Taylor
Robert Terkeltaub, MD
5Veterans Affairs Medical Center, University of California, San Diego, California, USA
Find articles by Robert Terkeltaub
Masanari Kuwabara, MD, PhD
6Department of Cardiology, Toranomon Hospital, Tokyo, Japan
7Division of Renal Diseases and Hypertension, School of Medicine, University of Colorado Denver, Aurora, Colorado, USA
Find articles by Masanari Kuwabara
Tony R Merriman, PhD
8Department of Biochemistry, University of Otago, Dunedin, New Zealand
Find articles by Tony R Merr